It works by attaching Herceptin to a drug called DM1, developed by ImmunoGen, which interferes with cancer cell growth. ImmunoGen will receive a $ 5 million milestone payment from Roche following the approval.

(This story corrects to remove reference to Japan approval from the third paragraph)